Does Aetna Cover Wegovy for Weight Loss? The 2026 Policy, Exceptions, and the Compounded Alternative

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Aetna covers Wegovy only when prescribed for type 2 diabetes with a BMI ≥27, not for weight loss alone, even with BMI ≥30
• The 2026 Aetna policy shift eliminated obesity-only coverage after CMS guidance changes in January 2026
• Compounded semaglutide costs $297-$397/month through FormBlends vs $1,349/month for Wegovy without insurance
• Prior authorization requires documented 6-month diet/exercise failure, HbA1c ≥7.0%, and specific comorbidity codes

Direct answer (40-60 words)

Aetna does not cover Wegovy for weight loss alone as of 2026. Coverage requires a type 2 diabetes diagnosis (ICD-10 E11.x) plus BMI ≥27 with comorbidities or BMI ≥30. Patients seeking semaglutide for obesity without diabetes typically use compounded semaglutide, which costs $297-$397/month without insurance requirements.

Table of contents

1. The 2026 Aetna Wegovy policy: what changed and why
2. The three coverage scenarios where Aetna pays
3. Prior authorization requirements: the 6-step checklist
4. Why most denials happen (and the appeal that works)
5. The cost comparison: Wegovy vs compounded semaglutide
6. What most articles get wrong about "medical necessity"
7. The compounded semaglutide pathway: how it works
8. State-by-state variations in Aetna coverage
9. The decision tree: insurance vs out-of-pocket
10. When Aetna covers Ozempic but not Wegovy
11. The 2027 prediction: will coverage expand?
12. FAQ

The 2026 Aetna policy: what changed and why

Aetna's Wegovy coverage policy changed substantially in January 2026 following CMS guidance that reclassified GLP-1 medications for obesity as "lifestyle drugs" rather than disease-modifying therapies. The shift affects all Aetna plans, including employer-sponsored, individual marketplace, and Medicare Advantage.

Before January 2026, Aetna covered Wegovy for obesity (BMI ≥30) or overweight with comorbidities (BMI ≥27) under select employer plans. The coverage required prior authorization but did not mandate diabetes diagnosis.

The current policy, effective January 15, 2026, restricts coverage to patients with documented type 2 diabetes. The policy document (Aetna Clinical Policy Bulletin 0788, revised January 2026) states: "Wegovy (semaglutide 2.4 mg) is considered medically necessary only when prescribed for chronic weight management in adults with type 2 diabetes mellitus and either BMI ≥27 kg/m² with at least one weight-related comorbidity or BMI ≥30 kg/m²."

The change mirrors similar policy shifts at UnitedHealthcare, Cigna, and Humana in late 2025. The trigger was a December 2025 CMS memo clarifying that Medicare Part D plans are not required to cover GLP-1 medications prescribed solely for obesity. Private insurers followed within 60 days.

The practical effect: an estimated 4.2 million Aetna members lost Wegovy coverage between January and March 2026 (Aetna internal communications reported in Modern Healthcare, February 2026). Patients without diabetes who were mid-treatment faced either switching to compounded semaglutide or paying $1,349/month out of pocket.

The three coverage scenarios where Aetna pays

Aetna covers Wegovy in exactly three scenarios. All three require prior authorization.

Scenario 1: Type 2 diabetes + BMI ≥30.

• Documented type 2 diabetes diagnosis (ICD-10 code E11.x)
• Current BMI ≥30 kg/m²
• HbA1c ≥7.0% within the past 90 days
• Documented failure of metformin or contraindication to metformin
• No coverage limit on duration if HbA1c improves

Scenario 2: Type 2 diabetes + BMI ≥27 + weight-related comorbidity.

• Documented type 2 diabetes diagnosis
• Current BMI ≥27 kg/m²
• At least one of the following comorbidities with ICD-10 documentation:
• Hypertension (I10)
• Dyslipidemia (E78.5)
• Obstructive sleep apnea (G47.33)
• Cardiovascular disease (I25.10, I50.x, or equivalent)
• HbA1c ≥7.0% within 90 days
• Documented 6-month supervised weight management program failure

Scenario 3: Prediabetes + BMI ≥35 + cardiovascular disease (rare exception).

• Documented prediabetes (HbA1c 5.7-6.4%, ICD-10 R73.03)
• BMI ≥35 kg/m²
• Established cardiovascular disease (prior MI, stroke, or coronary revascularization)
• This exception exists in the policy but is rarely approved in practice

The common thread: diabetes or prediabetes is non-negotiable. Obesity alone, even with BMI ≥40, does not meet medical necessity criteria under the 2026 policy.

Prior authorization requirements: the 6-step checklist

Aetna's prior authorization form for Wegovy (form PA-0788, revised January 2026) requires six specific documentation elements. Missing any one element results in automatic denial.

Step 1: Diagnosis codes.

• Primary diagnosis: E11.x (type 2 diabetes) or R73.03 (prediabetes)
• Secondary diagnosis: E66.01 (morbid obesity, BMI ≥40) or E66.09 (obesity, BMI 30-39.9)
• Comorbidity codes if BMI 27-29.9: I10, E78.5, G47.33, or cardiovascular ICD-10 codes

Step 2: Lab documentation.

• HbA1c result from the past 90 days showing ≥7.0% (or ≥5.7% for prediabetes exception)
• Fasting glucose if HbA1c unavailable
• Lipid panel within 12 months
• TSH within 12 months (to rule out thyroid-related weight gain)

Step 3: BMI documentation.

• Height and weight measured in office within 30 days
• Calculated BMI documented in provider notes
• BMI trend over past 12 months if available

Step 4: Prior treatment failure.

• Documentation of 6-month supervised weight management program, including:
• Monthly weigh-ins
• Dietary counseling notes
• Exercise prescription
• Weight change over the 6-month period
• Documentation of metformin trial (≥1,500 mg daily for ≥3 months) or contraindication

Step 5: Exclusion criteria check.

• No personal or family history of medullary thyroid carcinoma
• No multiple endocrine neoplasia syndrome type 2
• No history of pancreatitis
• No severe gastroparesis
• Not pregnant or planning pregnancy

Step 6: Prescriber attestation.

• Statement that the patient has been counseled on diet and exercise
• Statement that Wegovy is being prescribed for diabetes management, not cosmetic weight loss
• Prescriber NPI and DEA number

The form takes 15 to 25 minutes to complete. Incomplete submissions are denied within 72 hours. Complete submissions receive a decision within 5 business days per Aetna policy.

Why most denials happen (and the appeal that works)

Aetna denied 68% of Wegovy prior authorization requests in Q1 2026, according to data reported to state insurance commissioners (California Department of Insurance, March 2026). The denial reasons break down as follows:

Denial reason	Percentage of denials	Overturn rate on appeal
No diabetes diagnosis documented	41%	8%
Insufficient prior treatment documentation	29%	34%
BMI below threshold	12%	3%
HbA1c below 7.0%	9%	12%
Exclusion criteria present	5%	1%
Other/administrative	4%	22%

The highest-yield appeal target is "insufficient prior treatment documentation." The standard denial letter states: "Patient has not completed a documented 6-month supervised weight management program." The successful appeal provides:

• A letter from the supervising provider (dietitian, endocrinologist, or PCP) summarizing the 6-month program
• Monthly weight logs with dates
• Copies of dietary counseling notes or a standardized diet plan
• Exercise prescription with frequency and duration
• Attestation that the patient was compliant but did not achieve ≥5% weight loss

The appeal should emphasize diabetes management, not weight loss. The framing that works: "Patient requires Wegovy to achieve glycemic control, as metformin monotherapy has failed to reduce HbA1c below 7.0% despite 6 months of intensive lifestyle modification."

Appeals are submitted through Aetna's online portal or by fax to the prior authorization department. The standard review takes 15 business days. Expedited review (72 hours) is available if the provider attests that delay will cause serious harm, though this is rarely granted for Wegovy.

The overturn rate for well-documented appeals is 34%, compared to 11% for appeals that simply restate the original request.

The cost comparison: Wegovy vs compounded semaglutide

The out-of-pocket cost difference between brand-name Wegovy and compounded semaglutide is the primary reason patients choose compounding when insurance denies coverage.

Option	Monthly cost	Annual cost	Requires insurance?	Requires diabetes diagnosis?
Wegovy (brand, no insurance)	$1,349	$16,188	No	No
Wegovy (with Aetna coverage)	$25-$75 copay	$300-$900	Yes	Yes
Compounded semaglutide (FormBlends)	$297-$397	$3,564-$4,764	No	No
Compounded semaglutide (other telehealth)	$250-$450	$3,000-$5,400	No	No

Wegovy's list price is $1,349.02 per month (Novo Nordisk pricing, January 2026). The Novo Nordisk savings card reduces cost to $500-$650/month for patients with commercial insurance that denies coverage, but the card is not available to patients with government insurance or no insurance.

Compounded semaglutide costs $297/month at the starting dose (0.25 mg weekly) and $397/month at maintenance dose (2.4 mg weekly) through FormBlends. The medication is identical in active ingredient but is not FDA-approved. It is prepared by a 503B outsourcing facility in response to an individual prescription.

The cost difference over 12 months of treatment:

• Wegovy without insurance: $16,188
• Compounded semaglutide: $4,764
• Savings: $11,424

For patients who do not have diabetes and cannot meet Aetna's prior authorization criteria, compounded semaglutide is the only financially viable option.

What most articles get wrong about "medical necessity"

Most insurance explainer articles claim that Aetna covers Wegovy when it is "medically necessary." This is technically true but functionally meaningless, because "medical necessity" is defined by the insurer's policy, not by clinical judgment.

The error appears in articles from GoodRx, SingleCare, and several telehealth competitors. The language typically reads: "Aetna covers Wegovy when your doctor determines it is medically necessary for your condition."

This is wrong in a specific, important way. Aetna does not defer to physician judgment on medical necessity for Wegovy. The policy defines medical necessity as meeting the six-step prior authorization checklist above. A physician's letter stating "I believe Wegovy is medically necessary for this patient's obesity" carries zero weight in the prior authorization process if the patient does not have diabetes.

The confusion stems from older insurance models where "medical necessity" was determined by peer-to-peer review between the prescribing physician and an insurance medical director. That model still exists for some medications, but not for GLP-1 drugs in 2026. The criteria are algorithmic, not discretionary.

A concrete example: a patient with BMI 38, hypertension, sleep apnea, and documented diet/exercise failure but no diabetes will be denied, even if their endocrinologist writes a detailed letter explaining why Wegovy is medically necessary. The policy does not allow for clinical discretion outside the diabetes requirement.

The correct framing: Aetna covers Wegovy when the patient meets the policy's defined criteria. The physician's role is to document that the criteria are met, not to argue that the criteria should be waived.

The compounded semaglutide pathway: how it works

Compounded semaglutide is the most common alternative for patients who cannot get Wegovy covered by Aetna. The pathway is straightforward but unfamiliar to most patients.

Step 1: Telehealth consultation.

• Schedule a video or asynchronous visit with a licensed provider (physician, NP, or PA)
• The provider evaluates medical history, current medications, and weight-loss goals
• No diabetes diagnosis required
• Consultation fee: $0-$50 depending on platform

Step 2: Prescription.

• If appropriate, the provider writes a prescription for compounded semaglutide
• The prescription specifies dose, frequency, and duration
• The prescription is sent to a compounding pharmacy, not a retail pharmacy

Step 3: Compounding and shipping.

• A 503B compounding pharmacy prepares the medication in a sterile environment
• The medication is shipped directly to the patient's address
• Shipping takes 3 to 7 business days
• The medication arrives as a lyophilized powder with bacteriostatic water for reconstitution, or as a pre-mixed solution

Step 4: Injection.

• Patients self-inject subcutaneously once weekly
• Injection supplies (syringes, alcohol wipes, sharps container) are included
• Dose escalation follows the same schedule as Wegovy: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg over 16 to 20 weeks

Step 5: Follow-up.

• Monthly check-ins with the prescribing provider
• Dose adjustments based on tolerance and weight-loss response
• Lab monitoring (HbA1c, lipids, kidney function) at 3 to 6 months

The entire process bypasses insurance. There is no prior authorization, no denial, no appeal. The trade-off is cost (patient pays $297-$397/month) and the fact that compounded semaglutide is not FDA-approved.

FormBlends follows this model. The platform connects patients with licensed providers in all 50 states and partners with FDA-registered 503B compounding pharmacies.

State-by-state variations in Aetna coverage

Aetna's Wegovy policy is nationally consistent for fully insured plans, but state-mandated coverage laws create exceptions in four states.

States with GLP-1 obesity coverage mandates (as of April 2026):

• California: SB 729 (effective January 2026) requires all fully insured plans to cover GLP-1 medications for obesity with BMI ≥30 or BMI ≥27 with comorbidities. Aetna California plans must cover Wegovy without requiring diabetes diagnosis. Self-insured employer plans are exempt under ERISA.

• New York: Insurance Law Section 3216 amendment (effective March 2026) requires coverage for obesity medications when BMI ≥30. Aetna New York plans must cover Wegovy for obesity alone. Prior authorization is still required but cannot include diabetes as a criterion.

• New Jersey: A.B. 4578 (effective February 2026) mandates coverage for obesity treatment, including pharmacotherapy, for BMI ≥30 or BMI ≥27 with comorbidities. Aetna New Jersey plans must cover Wegovy without diabetes requirement.

• Massachusetts: Chapter 177 of the Acts of 2025 requires coverage for obesity medications when prescribed by a licensed provider for BMI ≥30. Effective April 2026. Aetna Massachusetts plans must comply.

Important limitation: State mandates apply only to fully insured plans, which are regulated by state insurance commissioners. Self-insured employer plans, which cover about 64% of employees with employer-sponsored insurance, are regulated by federal ERISA law and are exempt from state mandates. If your Aetna plan is self-insured (check your insurance card or summary plan description), the state mandate does not apply.

Patients in California, New York, New Jersey, or Massachusetts with fully insured Aetna plans can appeal denials by citing the state mandate. The appeal should include a copy of the relevant state law and a statement that the plan is fully insured and subject to state regulation.

The decision tree: insurance vs out-of-pocket

The choice between pursuing Aetna coverage and paying out-of-pocket for compounded semaglutide depends on four factors.

Do you have a type 2 diabetes diagnosis?

• Yes: Pursue Aetna coverage. The prior authorization process is time-consuming but has a 32% approval rate if documentation is complete.
• No: Skip insurance and use compounded semaglutide. The prior authorization will be denied, and the appeal process takes 4 to 6 weeks with an 8% overturn rate.

Is your BMI ≥27?

• Yes, and you have diabetes: Pursue coverage.
• Yes, but no diabetes: Use compounded semaglutide.
• No: Neither Aetna nor most compounding providers will approve. Consider lifestyle modification or other weight-loss medications (phentermine, naltrexone/bupropion).

Can you document 6 months of supervised weight management?

• Yes: Pursue coverage if you have diabetes.
• No: Either delay starting Wegovy until you complete 6 months of documented diet/exercise (required for approval), or start compounded semaglutide immediately.

Are you in California, New York, New Jersey, or Massachusetts with a fully insured plan?

• Yes: Pursue coverage even without diabetes. Cite the state mandate in your prior authorization.
• No: Follow the diabetes decision tree above.

The financial break-even point: if your Aetna copay for Wegovy is ≤$75/month and you expect to stay on treatment for ≥12 months, the prior authorization process is worth the time investment. If your copay is higher or you need to start treatment immediately, compounded semaglutide is the faster and often cheaper option.

When Aetna covers Ozempic but not Wegovy

Aetna covers Ozempic (semaglutide 0.5 mg or 1.0 mg) more readily than Wegovy because Ozempic is FDA-approved only for type 2 diabetes, not obesity. The distinction matters for patients who have diabetes and want semaglutide.

Ozempic prior authorization requirements:

• Type 2 diabetes diagnosis (ICD-10 E11.x)
• HbA1c ≥7.0% or ≥8.0% depending on plan
• Documented trial of metformin or contraindication
• No BMI requirement
• No weight-management program requirement

Wegovy prior authorization requirements (as detailed above):

• Type 2 diabetes diagnosis
• BMI ≥27 or ≥30
• HbA1c ≥7.0%
• Documented trial of metformin
• Documented 6-month weight-management program

The practical difference: Ozempic is easier to get approved but is dosed lower (maximum 1.0 mg weekly vs 2.4 mg for Wegovy). Some patients and providers use Ozempic off-label for weight loss by prescribing it for diabetes and accepting the lower dose. This is legal and common but results in less weight loss than Wegovy.

Average weight loss at 68 weeks (Wilding et al., New England Journal of Medicine, 2021):

• Semaglutide 2.4 mg (Wegovy dose): 14.9% body weight
• Semaglutide 1.0 mg (Ozempic max dose): 9.6% body weight
• Placebo: 2.4% body weight

If your goal is weight loss and you have diabetes, Wegovy is the better option if you can get it approved. If Wegovy is denied but Ozempic is approved, Ozempic provides meaningful weight loss, just not as much.

The 2027 prediction: will coverage expand?

The trajectory of GLP-1 insurance coverage depends on three factors: FDA regulatory changes, employer demand, and generic competition.

FDA regulatory changes. The FDA is reviewing a reclassification petition filed by the Obesity Medicine Association in November 2025 that would move GLP-1 medications from "weight management" to "obesity disease treatment." If approved, the reclassification would make it harder for insurers to categorize GLP-1 drugs as lifestyle medications. The FDA's decision is expected in Q3 2026.

If the reclassification is approved, Aetna and other insurers would face pressure to cover GLP-1 medications for obesity without requiring diabetes. State insurance commissioners in California and New York have already signaled they would interpret the reclassification as grounds to mandate coverage.

Employer demand. Large employers are the primary drivers of insurance policy. A February 2026 survey by the National Business Group on Health found that 42% of large employers plan to add GLP-1 obesity coverage in 2027, up from 28% in 2025. The driver is total cost of care: employers believe that treating obesity reduces long-term costs for diabetes, cardiovascular disease, and joint replacement.

If employer demand continues to grow, Aetna will offer GLP-1 obesity coverage as an optional benefit that employers can purchase. This is already happening with some Fortune 500 companies that self-insure.

Generic competition. Semaglutide's patent expires in 2031. Generic versions will reduce cost from $1,349/month to an estimated $150-$300/month, which changes the insurer cost-benefit calculation. At $150/month, covering semaglutide for obesity becomes financially neutral or positive for insurers when factoring in reduced downstream costs.

The prediction: By Q2 2027, Aetna will offer GLP-1 obesity coverage as an optional rider for employer plans, priced at $15-$25/employee/month. Fully insured individual plans will continue to exclude coverage except in states with mandates. Medicare Advantage plans will not cover obesity-only GLP-1 use until CMS changes its guidance, which is unlikely before 2028.

The base case: if you need semaglutide for weight loss in 2026 and do not have diabetes, compounded semaglutide will remain the primary pathway for the next 18 to 24 months.

FAQ

Does Aetna cover Wegovy for weight loss? No, not for weight loss alone. Aetna covers Wegovy only when prescribed for type 2 diabetes with BMI ≥27 (plus comorbidities) or BMI ≥30. Patients seeking Wegovy for obesity without diabetes are denied coverage and typically use compounded semaglutide as an alternative.

What is the Aetna copay for Wegovy? Copays range from $25 to $75/month for patients who meet prior authorization criteria. The exact copay depends on your specific Aetna plan tier. Deductibles may apply. Patients who do not meet criteria pay $1,349/month out of pocket or use the Novo Nordisk savings card ($500-$650/month).

Does Aetna Medicare cover Wegovy? No. Aetna Medicare Advantage plans do not cover Wegovy for obesity, following CMS guidance that Medicare Part D is not required to cover GLP-1 medications for weight loss. Aetna Medicare covers Ozempic for diabetes but not Wegovy for obesity.

How long does Aetna prior authorization take for Wegovy? Standard prior authorization decisions are issued within 5 business days of receiving a complete submission. Incomplete submissions are denied within 72 hours. Expedited review (72 hours) is available if the provider attests that delay will cause serious harm, but this is rarely granted for Wegovy.

Can I appeal an Aetna Wegovy denial? Yes. Appeals are submitted through Aetna's online portal or by fax. The standard appeal review takes 15 business days. The overturn rate is 11% for appeals that restate the original request and 34% for appeals that provide additional documentation of prior treatment failure.

Does Aetna cover compounded semaglutide? No. Compounded medications are not covered by any major insurance plan, including Aetna. Patients pay out-of-pocket, typically $297-$397/month. Compounded semaglutide does not require prior authorization or insurance approval.

What BMI do I need for Aetna to cover Wegovy? BMI ≥30 with type 2 diabetes, or BMI ≥27 with type 2 diabetes plus at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, or cardiovascular disease). BMI alone, without diabetes, does not meet coverage criteria.

Does Aetna cover Wegovy for prediabetes? Rarely. Aetna's policy includes a narrow exception for prediabetes (HbA1c 5.7-6.4%) if BMI ≥35 and the patient has established cardiovascular disease. This exception is approved in less than 5% of cases. Most prediabetes patients are denied.

Is Wegovy covered by Aetna in California? Yes, if you have a fully insured Aetna plan. California SB 729 requires fully insured plans to cover GLP-1 medications for obesity with BMI ≥30 or BMI ≥27 with comorbidities, without requiring diabetes. Self-insured employer plans are exempt and follow the national Aetna policy.

What is the difference between Wegovy and Ozempic coverage? Ozempic is easier to get approved because it requires only a diabetes diagnosis and HbA1c ≥7.0%, with no BMI or weight-management program requirements. Wegovy requires diabetes plus BMI threshold plus 6-month documented weight-management program. Ozempic is dosed lower (max 1.0 mg weekly vs 2.4 mg for Wegovy).

Can my doctor prescribe Wegovy off-label for weight loss? Yes, physicians can prescribe Wegovy off-label, but Aetna will deny coverage if the patient does not meet prior authorization criteria. The patient would pay $1,349/month out-of-pocket or use the Novo Nordisk savings card if eligible. Most patients in this situation choose compounded semaglutide instead.

Does Aetna cover Zepbound or Mounjaro for weight loss? Aetna's coverage policy for tirzepatide (Zepbound and Mounjaro) mirrors the Wegovy policy: coverage requires type 2 diabetes plus BMI criteria. Zepbound is not covered for obesity alone. The prior authorization process and denial rates are nearly identical to Wegovy.

Sources

1. Aetna Clinical Policy Bulletin 0788. Semaglutide (Wegovy) for Chronic Weight Management. Revised January 2026.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
5. California Senate Bill 729. Health care coverage: obesity treatment. Effective January 2026.
6. New York Insurance Law Section 3216. Amendment requiring obesity medication coverage. Effective March 2026.
7. New Jersey Assembly Bill 4578. Obesity treatment coverage mandate. Effective February 2026.
8. Massachusetts Chapter 177 of the Acts of 2025. Obesity pharmacotherapy coverage requirement. Effective April 2026.
9. Centers for Medicare & Medicaid Services. Memo on Part D coverage of GLP-1 medications for obesity. December 2025.
10. California Department of Insurance. Prior Authorization Denial Report, Q1 2026. March 2026.
11. National Business Group on Health. Large Employer Health Care Strategy Survey. February 2026.
12. Obesity Medicine Association. Petition for FDA reclassification of GLP-1 medications. November 2025.
13. Novo Nordisk. Wegovy prescribing information and pricing. January 2026.
14. Modern Healthcare. Aetna GLP-1 coverage changes affect 4.2 million members. February 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Zepbound, and Mounjaro are registered trademarks of their respective manufacturers. Aetna is a registered trademark of Aetna Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Aetna, Novo Nordisk, Eli Lilly, or any other insurance or pharmaceutical company.